Nattokinase Research Gaps and Unanswered Questions

Introduction

Nattokinase has been studied for nearly four decades since its discovery in 1987. Yet the evidence base remains surprisingly thin compared to pharmaceutical cardiovascular therapies. The largest trial to date enrolled only 265 participants. Most studies have been small, short-term, and conducted in healthy volunteers or patients with modest cardiovascular risk. This matters because the people most likely to consider nattokinase often have established disease or elevated risk markers that place them outside the populations actually studied.

Understanding what we do not know is as important as understanding what we do. Research gaps represent both uncertainty and opportunity. They also explain why mainstream cardiology has not embraced nattokinase despite decades of interest in the compound. This article examines the studies most needed to clarify benefit and risk, explores why the evidence has accumulated so slowly, and considers what would need to change for nattokinase to move from supplement aisle to standard of care.

The questions here connect to practical decisions covered in integrating nattokinase with standard care and the safety considerations that become especially important when evidence is incomplete.

What studies are most needed to clarify benefit and risk?

The most critical gap is the absence of large, long-term trials with hard clinical endpoints. Existing studies measure surrogate markers like blood pressure, lipid levels, or carotid intima-media thickness. These outcomes matter, but they do not directly answer whether nattokinase prevents heart attacks, strokes, or cardiovascular death. A 2023 meta-analysis pooling six randomized trials found only 546 total participants across all studies combined, limiting the power to detect meaningful clinical effects (Li et al., 2023).

Head-to-head comparisons against established therapies are almost nonexistent. One Chinese trial compared nattokinase to simvastatin for carotid atherosclerosis, but it enrolled only 76 patients over 26 weeks (Ren et al., 2017). No trials compare nattokinase to antiplatelet agents like aspirin or anticoagulants like warfarin in populations where those drugs are indicated. Without such comparisons, determining where nattokinase might fit in a treatment hierarchy is impossible.

Safety studies in high-risk populations remain inadequate. The largest prospective safety study enrolled 153 patients with vascular diseases, but follow-up was limited and bleeding events were not systematically adjudicated (Gallelli et al., 2021). Patients on anticoagulation, those with prior bleeding, and those with severe renal or hepatic impairment have essentially no safety data to guide decisions.

Why is the evidence base still limited despite decades of interest?

The economics of supplement research create structural barriers. Nattokinase cannot be patented as a novel compound. Any company investing in large clinical trials would generate data that competitors could use without bearing the research costs. This free-rider problem explains why pharmaceutical-grade trials almost never happen for dietary supplements. The Hodis trial of 265 participants was funded through NIH grants and industry collaboration, a rare combination that is difficult to replicate (Hodis et al., 2021).

Regulatory incentives compound the problem. In the United States, supplements can be marketed without demonstrating efficacy for disease treatment. Companies have little financial motivation to prove therapeutic claims when they can sell products without that burden. In Japan, where natto has cultural significance, nattokinase is classified as a functional food with permissible health claims, reducing pressure for rigorous clinical validation.

Academic interest has been sporadic and geographically concentrated. Most mechanistic and early clinical work originated in Japan. Western cardiovascular research has focused on pharmaceutical development where intellectual property protections exist. The result is a compound with plausible biological effects supported primarily by small studies from a limited number of research groups.

What would it take for nattokinase to become standard of care?

Adoption into clinical guidelines would require randomized controlled trials demonstrating reduced cardiovascular events in relevant patient populations. The bar for cardiovascular therapies is high. Aspirin’s role in secondary prevention rests on trials enrolling tens of thousands of patients. Statins have been tested in trials with over 100,000 participants collectively. Nattokinase would need comparable evidence, which would cost hundreds of millions of dollars to generate.

Standardization of products and dosing would also be necessary. Current supplements vary in potency and purity, making it difficult to translate research findings into clinical recommendations. A review of nattokinase pharmacology noted that fibrinolytic unit measurements are not uniform across manufacturers (Weng et al., 2017). Pharmaceutical development would require consistent manufacturing standards that the supplement industry does not currently meet.

Regulatory pathways could theoretically accelerate adoption. If nattokinase were developed as a drug rather than a supplement, it could pursue FDA approval with exclusivity protections that justify research investment. However, no company has pursued this route, likely because the compound’s long history as a food makes novel drug approval uncertain and because generic competition would emerge immediately after any exclusivity period ended.

Are there subpopulations more likely to benefit?

Theoretical rationale suggests patients with elevated fibrinogen or impaired fibrinolysis might derive particular benefit. Nattokinase degrades plasminogen activator inhibitor-1, which opposes the body’s natural clot-dissolving machinery (Urano et al., 2001). Individuals with elevated PAI-1 levels might therefore respond more robustly. However, no trials have stratified outcomes by baseline fibrinolytic markers.

Patients with elevated Lp(a) represent another plausible target population. Lp(a) carries prothrombotic properties and resists modification by statins or lifestyle changes. Whether nattokinase’s fibrinolytic effects might partially offset Lp(a)-associated risk is unknown. No published studies have examined nattokinase specifically in patients selected for elevated Lp(a).

Populations intolerant of standard therapies could be another niche. Patients who cannot take aspirin due to bleeding or allergy, or those who decline anticoagulation, might consider nattokinase as a less potent alternative. This use pattern exists in clinical practice but lacks evidence to support or refute it. The safety profile in vascular surgery patients suggests tolerability but does not establish efficacy for thrombosis prevention (Gallelli et al., 2021).

What biomarkers could help personalize the decision?

Fibrinolytic markers offer the most direct connection to nattokinase’s mechanism. D-dimer levels reflect ongoing fibrin turnover. PAI-1 activity measures resistance to clot breakdown. Tissue plasminogen activator antigen quantifies the body’s endogenous fibrinolytic capacity. A crossover trial in healthy volunteers showed nattokinase altered several coagulation parameters, including factor VIII activity and fibrinogen levels (Kurosawa et al., 2015). Whether baseline values predict response magnitude is unexplored.

Inflammatory markers might also prove relevant. The Wu et al. study demonstrating anti-inflammatory effects suggests nattokinase could benefit patients with elevated inflammatory burden (Wu et al., 2020). C-reactive protein, interleukin-6, or other inflammatory markers might identify responders, but this hypothesis remains untested in humans.

Genetic polymorphisms affecting coagulation and fibrinolysis could theoretically influence nattokinase response. Variants in genes encoding PAI-1, tissue plasminogen activator, or fibrinogen affect baseline clotting tendency. Pharmacogenomic approaches have transformed warfarin dosing but have not been applied to nattokinase. Until such studies occur, biomarker-guided use remains speculative rather than evidence-based.

Conclusion

Nattokinase research sits in a frustrating middle ground. There is enough evidence to suggest biological plausibility and potential benefit, but not enough to establish efficacy for meaningful clinical outcomes. The studies that would resolve this uncertainty are unlikely to happen under current economic and regulatory structures. This leaves consumers and clinicians to make decisions based on incomplete information.

The practical implication is appropriate humility. Nattokinase may help, but we cannot say with confidence that it does. Patients considering it should understand they are making a judgment call in the face of uncertainty, not following established evidence. The economic considerations and product quality concerns become more important precisely because the clinical evidence is weak. When science cannot definitively guide a decision, other factors necessarily play a larger role.

For those who choose to try nattokinase, the approach should acknowledge what we do not know. Monitoring for adverse effects matters more when safety data is limited. Discussing the decision with a physician remains important even when that physician may have limited familiarity with the compound. And maintaining realistic expectations about benefits helps avoid both false hope and unnecessary disappointment.